KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Cash (2018 - 2025)

Historic Change in Cash for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Q3 2025 value amounting to $20.2 million.

  • Aurinia Pharmaceuticals' Change in Cash rose 44048.19% to $20.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.0 million, marking a year-over-year increase of 48948.68%. This contributed to the annual value of $34.6 million for FY2024, which is 17629.2% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Change in Cash stood at $20.2 million, which was up 44048.19% from -$13.4 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Change in Cash high stood at $174.3 million for Q4 2021, and its period low was -$115.8 million during Q1 2021.
  • Its 5-year average for Change in Cash is -$10.5 million, with a median of -$7.3 million in 2023.
  • Data for Aurinia Pharmaceuticals' Change in Cash shows a peak YoY increase of 176807.91% (in 2024) and a maximum YoY decrease of 32571.98% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Change in Cash stood at $174.3 million in 2021, then crashed by 95.34% to $8.1 million in 2022, then plummeted by 69.48% to $2.5 million in 2023, then skyrocketed by 1768.08% to $46.3 million in 2024, then plummeted by 56.39% to $20.2 million in 2025.
  • Its last three reported values are $20.2 million in Q3 2025, -$13.4 million for Q2 2025, and -$17.0 million during Q1 2025.